Registry to evaluate pitolisant use during pregnancy
Official title: WAKIX® (Pitolisant) Pregnancy Registry: An Observational Study of the Safety of Pitolisant Exposure in Pregnant Women and Their Offspring
Run by Harmony Biosciences Management, Inc. · NCT05536011 · Data updated 2026-11-12
This study is trying to see how using pitolisant during pregnancy affects mothers and their babies, and it's open to pregnant women with and without narcolepsy.
Quick facts
| Study type | Observational |
|---|---|
| Sex | Women only |
| Enrollment | 1329 (estimated) |
| Sponsor | Harmony Biosciences Management, Inc. Industry-sponsored |
| Locations | 1 site (Morrisville, North Carolina) |
| Status | Recruiting |
| Started | August 24, 2021 |
| Main results expected | June 30, 2030 |
| Study ends | June 30, 2030 |
| Registry record updated | June 12, 2026 |
| Trial ID | NCT05536011 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include pregnant women of any age who have been exposed to pitolisant or comparator products.
✕Probably not a fit
Patients who have already experienced pregnancy outcomes prior to contacting the registry will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The WAKIX Pregnancy Registry is a prospective, observational cohort study in the US that aims to assess the effects of pitolisant exposure during pregnancy on maternal, fetal, and infant outcomes. Pregnant women who consent to participate will have their data collected from routine medical records, with no additional tests required. The study includes women with and without narcolepsy who have been exposed to pitolisant or comparator products. The registry follows FDA guidelines for pregnancy exposure studies.
Why it matters
Potential benefit: If successful, this registry could provide valuable insights into the safety and effects of pitolisant during pregnancy, guiding treatment decisions for pregnant women with narcolepsy.
How similar studies have gone: While observational studies on medication exposure during pregnancy are common, this specific registry approach for pitolisant is novel and untested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Pregnant woman of any age * Consent to participate * Authorization for her HCP(s) to provide data to the registry * For participants with a diagnosis of narcolepsy: exposure to at least one dose of pitolisant or one dose of a comparator product, or, unexposed to pitolisant or comparator products at any time during pregnancy (i.e., any pregnant woman with a diagnosis of narcolepsy) * For participants without a diagnosis of narcolepsy: exposure to at least one dose of pitolisant or one dose of a comparator product at any time during pregnancy Exclusion Criterion: • Occurrence of pregnancy outcome prior to first contact with the Registry Coordination Center (RCC) (i.e., retrospectively enrolled)
Where it's running
-
Evidera (PPD)
Morrisville, North Carolina, United States Recruiting
Study contacts
- Study coordinator: WAKIX Pregnancy Registry Associate
- Email: wakixpregnancyregistry@ppd.com
- Phone: 1-877-302-2813
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Prenatal education to reduce environmental exposures during pregnancy
Aimed at pregnant people, this program tests whether a classroom-style education can help reduce exposure to harmful pollutants from seafood and nearby pollution sources.
-
Interprofessional Training to Improve Care for Peri-Delivery Patients with Substance Use Disorder
This program tests INSPIRE, a set of online and in-person trainings for healthcare teams to reduce stigma and improve care for people with substance use disorder around labor, delivery, and postpartum at the University of Utah.
-
Lower-extremity blood pressure monitoring during cesarean under spinal anesthesia
This study tests whether noninvasive blood pressure monitoring from the toe is better than the arm at predicting neonatal outcomes during cesarean delivery with spinal anesthesia.
-
HBS-301 for Narcolepsy: daily wakefulness and sleepiness improvement in adults
This Phase 3 study tests HBS-301 vs placebo in adults with narcolepsy to see if it helps with daytime sleepiness, cataplexy, sleepiness, and fatigue.
-
Expanded-dosing Xywav vs placebo in narcolepsy and IH
This study tests whether expanded nightly dosing of Xywav helps adults with narcolepsy or idiopathic hypersomnia, compared with placebo.
-
Testing Lu AH69593 for safety and tolerance in healthy adults and people with narcolepsy
This study tests whether Lu AH69593 is safe and well tolerated in adults, including those with narcolepsy, and looks at how the body processes the drug with and without food.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.